Forbes.com has run a number of screens--sifting through biotech funds and biotech-heavy health care funds to separate those that are least risky from those that really goouton a limb.
With odds that low, maybe it is not surprising that the III is willing to goouton a limb and say that if it happened, your standard policy is likely to cover it.